Research programme: TGF-beta antisense oligonucleotides - Isarna Therapeutics

Drug Profile

Research programme: TGF-beta antisense oligonucleotides - Isarna Therapeutics

Alternative Names: ASPH-0047; ASPH-1047; ASPH-1106; ISTH0047

Latest Information Update: 13 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isarna Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Transforming growth factor beta1 inhibitors; Transforming growth factor beta2 inhibitors; Transforming growth factor beta3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Fibrosis; Glaucoma

Most Recent Events

  • 09 Jan 2015 Preclinical trials in Fibrosis in Germany (Parenteral)
  • 09 Jan 2015 Preclinical trials in Glaucoma in Germany before January 2015 (Parenteral)
  • 09 Jan 2015 Isarna files a clinical trial application with the National Organization for Medicines in Germany for Glaucoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top